Factors that Influence the 5-Year Survival Rate of Human Immunodeficiency Virus (HIV) - Acquired Immuno Deficiency Syndrome (AIDS) Patients in Kariadi Hospital Semarang Indonesia

Muchlis Achsan Udji

Abstract


HIV/AIDS is one of the diseases that cause death in many countries, and it requires serious attention. Survival rate of the HIV/AIDS patients is determined by many factors, like viral load, CD4, age, gender, clinical stage, depression, and family support. This research was intended to discover the factors that influence the 5-year survival rate of patients with HIV/AIDS in Dr. Kariadi Hospital Semarang. This research was an observational analytic study using cohort retrospective method with 108 samples. Data is collected from medical record and then tested using chi square statistic test. In this research, patients who survived the 5 years: 48 (62.3 %) male patients, 64 (66.7 %) patients were under 45 years old, 32 (76 %) patients were clinical stage I and II, 43 (75.4 %) patients with CD4 count above 50 cell/mm3, 61 (92 %) viral load < 400 copy/ml. From the four variables (viral load, CD4, age, gender), clinical stage I-II (p = 0.010), CD4 count > 50 cell/ml (p = 0.001) and viral load < 400 copy/ml (p = 0.001) were influence the 5-year survival rate of HIV/AIDS patients. On the other hand, gender (p = 0.680) and age (p = 0.205) weren’t influence. Factors that influence the 5-year survival rate of HIV/AIDS patients in Dr. Kariadi Hospital Semarang were clinical stage I-II, CD4 count  > 50 cells/ml and viral load < 400 copy/ml, while factors that have no affect to 5-year survival rate were gender and age.

Keywords


HIV/AIDS, 5-year survival rate, clinical stage, CD4, viral load

Full Text:

PDF

References


WHO. HIV/AIDS. Available from : http://www.who.int/topics/hiv_aids /en/.

Centers for Disease Control and Prevention. Basic information about HIV and AIDS. Available from: http://www.cdc.gov/hiv/topics/basic/.

Sofro MAU, Anurogo D. Kewaspadaan universal dalam menangani penderita HIV/AIDS. In: 5 Menit Memahami 55 Problematika Kesehatan. Editor: Wee D. Jogjakarta: D-Medika; 2013. p. 143-8.

Komisi Penanggulangan AIDS Nasional. Situasi HIV dan AIDS di Indonesia. Jakarta; 2009.

Direktorat Jendral PP dan PL Kementrian Kesehatan RI. Laporan Situasi Perkembangan HIV/AIDS di Indonesia s.d. 30 Juni 2012. Jakarta (Indonesia); 2012.

Astari L, Sawitri, Safitri YE, Hinda D. Viral load pada infeksi HIV. Berkala Ilmu Kesehatan Kulit dan Kelamin. 2009; 21(1):31-8.

Farzadegan H, Hoover DR, Astemborski J, Lyles CM, Margolick JB, Markham RB et al. Sex differences in HIV-1 viral load and progression to AIDS. The Lancet.1998; 352(9139):1510-4.

Fang CT, Chang YY, Hsu HM, Twu SJ, Chen KT, Lin CC et al. Life expectancy of patients with newly diagnosed HIV infection in the era of highly active antiretroviral therapy. Q J Med. 2007;100:97-105.

Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries. Annals of Internal Medicine. 2011; 155(4):209-15.

Nasronudin. Pengembangan pengetahuan penyakit infeksi HIV dan AIDS. In: HIV dan AIDS Pendekatan Biologi Molekuler, Klinis, dan Sosial. Editor: Barakbah J, Soewandojo E, Suharto, Hadi U, Astuti WD. Surabaya: Airlangga University Press; 2007. p. 279-303.

Vella S, M Guiliano, M Floridia, A Chiesi , C Tomino, A Seeber et al. Effect of sex, age, and transmission cathegory on the progression to AIDS and survival of Zidovudin-treated symptomatic patients. AIDS.1995; 9(1):51-6. (Abstrak).

Direktorat Jendral PP dan PL Kementrian Kesehatan RI. Laporan Situasi Perkembangan HIV/AIDS di Indonesia s.d. 31 Maret 2013. Jakarta (Indonesia); 2013.

Santoro LG, Harrison LH, Moulton LH, Lima LAA, de Pinho AMF, Hofer C et al. Gender and survival after AIDS in Rio de Janeiro, Brazil. Journal of Acquired Immune Deficiency Syndromes. 1998; 19(4):403-7.

Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial Plasma HIV-1 RNA Level and Progression To AIDS in Women And Men. N Engl J Med. 2001; 344(10):720-5.

Babiker A, Darby S, De Angelis D, Kwart D, Porter K, Beral V et al. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy. Lancet. 1999; 355(9210):1131-7. (Abstrak).

Nguyen N, Holodny M. HIV infection in ederly. Clin Interv Aging. 2008; 3(3): 453-72.

French N, Mujugira A, Nakiyingi J, Mulder D, Janof EN, Gilks CF. Immunologic and clinical stages in HIV-1 infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advance disease. Journal of Acquired Immune Deficiency Syndromes. 1999; 22(5):509-16.

Malamba SS, Morgan D, Clayton T, Mayanja B, Okongo M, Whithword J, “The prognostic value of the World Health Organisation staging system for HIV infection and disease in rural Uganda”, Journal of The International AIDS Society, 1999, 13(18):2555-62.

Ehmann WC, Eyster ME, Wilson SE, Andes GA, Goedert JJ, “Relationship of CD4 lymphocyte counts to survival in a cohort of hemophiliacs infected with HIV”, Journal of Acquired Immune Deficiency Syndromes, 1994, 7(10):1095-8.

Hogg R, V Lima, JA Sterne, S Grabar, M Battegay, M Bonarek, “Life expectancy of individuals on combination antiretroviral therapy in high-income countries”, Lancet, 2008, 372(9635):293-9.

Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N, “Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy in Uganda”, AIDS, 2011, 25(6):851–5.


Refbacks

  • There are currently no refbacks.




Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.